Sorafenib-induced palmoplantar hyperkeratosis
Lountzis, N.I.; Maroon, M.S.
Journal of Drugs in Dermatology Jdd 7(6): 588-589
2008
ISSN/ISBN: 1545-9616 PMID: 18561593 Document Number: 14978
Sorafenib is an oral multikinase inhibitor used in the treatment of renal cell carcinoma. As with single kinase inhibitors, cutaneous adverse events have been reported with sorafenib, specifically a hand-foot reaction complicated by hyperkeratosis. The authors highlight the case of a 51-year-old Caucasian woman treated for metastatic renal cell carcinoma who presented with well-defined tender erythematous callosities of the fingers and feet, following a dosage increase of sorafenib. A dose reduction decreased the symptoms, but the hyperkeratosis persisted. This adverse response may represent a novel event differing from traditional hand-foot syndrome.
Document emailed within 1 workday
